7D1M image
Entry Detail
PDB ID:
7D1M
Keywords:
Title:
CRYSTAL STRUCTURE OF THE SARS-CoV-2 MAIN PROTEASE COMPLEXED WITH GC376
Biological Source:
PDB Version:
Deposition Date:
2020-09-14
Release Date:
2020-10-28
Method Details:
Experimental Method:
Resolution:
1.35 Å
R-Value Free:
0.15
R-Value Work:
0.11
R-Value Observed:
0.11
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:3C-like proteinase
Chain IDs:A, B
Chain Length:307
Number of Molecules:2
Biological Source:Severe acute respiratory syndrome coronavirus 2
Primary Citation
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
Nat Commun 11 4417 4417 (2020)
PMID: 32887884 DOI: 10.1038/s41467-020-18233-x

Abstact

COVID-19 was declared a pandemic on March 11 by WHO, due to its great threat to global public health. The coronavirus main protease (Mpro, also called 3CLpro) is essential for processing and maturation of the viral polyprotein, therefore recognized as an attractive drug target. Here we show that a clinically approved anti-HCV drug, Boceprevir, and a pre-clinical inhibitor against feline infectious peritonitis (corona) virus (FIPV), GC376, both efficaciously inhibit SARS-CoV-2 in Vero cells by targeting Mpro. Moreover, combined application of GC376 with Remdesivir, a nucleotide analogue that inhibits viral RNA dependent RNA polymerase (RdRp), results in sterilizing additive effect. Further structural analysis reveals binding of both inhibitors to the catalytically active side of SARS-CoV-2 protease Mpro as main mechanism of inhibition. Our findings may provide critical information for the optimization and design of more potent inhibitors against the emerging SARS-CoV-2 virus.

Legend

Protein

Chemical

Disease

Primary Citation of related structures